To read the full story, subscribe or sign in.

Okogen begins phase II trial in Australia with topical ranpirnase to fight adenoviral conjunctivitis

Aug. 14, 2019

PERTH, Australia – San Diego-based Okogen Inc. is taking its clinical trial program to Australia where it will test its lead compound OKG-0301 for acute adenoviral conjunctivitis in the phase II (RUBY) trial.

BioWorld Asia Clinical

Bio Korea 2026 kicks off with spotlight on oligonucleotides

BioWorld

Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...

Chinese biotechs gain leverage as partners in dealmaking

BioWorld

China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...

University of Western Australia patents 5-HT2A/B modulators

BioWorld Science

University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...

AA meeting of minds as PTC, Novartis push votoplam in HD

BioWorld

What PTC Therapeutics Inc.’s latest data with votoplam might mean in the Huntington’s disease (HD) landscape became grist for Wall Street after the firm unveiled...

Innervation can slow, as well as speed, tumor growth, study finds

BioWorld

Innervation by the sympathetic nervous system is typically a boon to tumors. But researchers from Weill Cornell Medicine and colleagues have shown that in some...